Erythema Nodosum–Like Panniculitis in Patients With Melanoma Treated With Vemurafenib

Rishika Sinha, Kim Edmonds, Julia Newton-Bishop, Martin Gore, James Larkin, Louise Fearfield
2013 Journal of Clinical Oncology  
Melanoma a type of skin cancer derived from melanocytes which represents around 4% of all skin cancers recorded till date, but is responsible for 80% deaths due to skin tumors. The development of new targeted therapies directed specifically against malignant cells has brought hope to the treatment of melanoma patients. The first drugs developed against specific molecules were BRAF inhibitors, designed for the treatment of metastatic melanoma. These drugs have been demonstrated to improve both
more » ... erall and disease-free survival in these patients. At the same time, a wide range of adverse events (AEs) have emerged from their use. Some of them are quite frequent and are observed regularly in everyday practice on the other hand, there are rare AEs that require an early diagnosis for adequate treatment so knowledge of their existence is crucial for timely recognition and patient management. We here have presented a case of erythema nodosum-like septal panniculitis in a patient receiving therapy with vemurafenib and cobimetinib. BRAFi-associated panniculitis -an emerging side effect with a variable histological picture: report of two cases and review of the literature. J Cutan Pathol 44: 307-309. Citation: Tapial JM, Oñate CV, Martínez-Doménech Á, Ferrer DS, Pastor GP, et al. (2019) Erythema Nodosum-like Panniculitis Associated with the Use of Vemurafenib. J Clin Exp Dermatol Res 10: 481.
doi:10.1200/jco.2012.45.8307 pmid:23715570 fatcat:ytenomr6zvhyxbxrbllv4cvksy